International Clinical Trial: Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian Cancer

Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07117877) titled 'Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian Cancer' on Aug. 5.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Fudan University

Condition: Platinum Resistant Ovarian Cancer Platinum Refractory Epithelial Ovarian Cancer Ovarian Cancer (OvCa)

Intervention: Drug: Etoposide Capsules Drug: Bevacizumab

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: Septemb...